# YS Biopharma Co. Ltd. (YS)

Source: https://www.quantisnow.com/company/YS
Generated: 2026-11-13T18:19:05.468Z

- Ticker: YS
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations

## Latest YS news and filings

- 2024-11-07 13:00 UTC [LakeShore Biopharma Initiates Biologics License Application of PIKA Rabies Vaccine to the Drug Regulatory Authority of Pakistan](https://www.quantisnow.com/insight/lakeshore-biopharma-initiates-biologics-license-application-of-pika-rabies-vaccine-5757724)
- 2024-05-24 11:45 UTC [SEC Form 6-K] [SEC Form 6-K filed by YS Biopharma Co. Ltd.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-ys-biopharma-co-ltd-5515380)
- 2024-05-24 11:33 UTC [Market Chatter] [YS Biopharma Changes Its Legal Name To LakeShore Biopharma Co., Ltd.; Ticker Symbol To Change To 'LSB'](https://www.quantisnow.com/insight/ys-biopharma-changes-its-legal-name-to-lakeshore-biopharma-co-5515346)
- 2024-05-24 11:30 UTC [YS Biopharma Announces Name Change to LakeShore Biopharma](https://www.quantisnow.com/insight/ys-biopharma-announces-name-change-to-lakeshore-biopharma-5515327)
- 2024-05-21 20:30 UTC [SEC Form 6-K] [SEC Form 6-K filed by YS Biopharma Co. Ltd.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-ys-biopharma-co-ltd-5507735)
- 2024-05-21 20:15 UTC [YS Biopharma Announces Results of Extraordinary General Meeting](https://www.quantisnow.com/insight/ys-biopharma-announces-results-of-extraordinary-general-meeting-5507480)
- 2024-05-20 20:16 UTC [SEC Form S-8] [SEC Form S-8 filed by YS Biopharma Co. Ltd.](https://www.quantisnow.com/insight/sec-form-s-8-filed-by-ys-biopharma-co-ltd-5504221)
- 2024-05-08 12:32 UTC [SEC Form 424B3] [SEC Form 424B3 filed by YS Biopharma Co. Ltd.](https://www.quantisnow.com/insight/sec-form-424b3-filed-by-ys-biopharma-co-ltd-5470335)
- 2024-05-07 20:30 UTC [SEC Form 6-K] [SEC Form 6-K filed by YS Biopharma Co. Ltd.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-ys-biopharma-co-ltd-5467661)
- 2024-05-07 20:20 UTC [Leadership Update] [YS Biopharma to Hold Extraordinary General Meeting on May 21, 2024 and Announces the Appointment of Interim Chief Executive Officer](https://www.quantisnow.com/insight/ys-biopharma-to-hold-extraordinary-general-meeting-on-may-21-5467423)
- 2024-04-29 12:15 UTC [SEC Form 6-K] [SEC Form 6-K filed by YS Biopharma Co. Ltd.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-ys-biopharma-co-ltd-5439522)
- 2024-04-29 12:02 UTC [Market Chatter] [YS Biopharma Receives 180 Day Extension By Nasdaq To Regain Compliance With Minimum Bid Price Rule](https://www.quantisnow.com/insight/ys-biopharma-receives-180-day-extension-by-nasdaq-to-regain-5439445)
- 2024-04-29 12:00 UTC [YS Biopharma Receives Additional 180 Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule](https://www.quantisnow.com/insight/ys-biopharma-receives-additional-180-day-extension-by-nasdaq-to-5439407)
- 2024-04-19 12:03 UTC [SEC Form 6-K] [SEC Form 6-K filed by YS Biopharma Co. Ltd.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-ys-biopharma-co-ltd-5420091)
- 2024-04-19 11:13 UTC [Market Chatter] [YS Biopharma Co 9M 2024 EPS Loss Of RMB (1.04) Versus RMB (2.71) YoY](https://www.quantisnow.com/insight/ys-biopharma-co-9m-2024-eps-loss-of-rmb-104-5419926)
- 2024-04-19 11:12 UTC [Market Chatter] [YS Biopharma Co 9M 2024 Sales Of $61.9M](https://www.quantisnow.com/insight/ys-biopharma-co-9m-2024-sales-of-619m-5419923)
- 2024-04-19 11:00 UTC [Earnings Date] [YS Biopharma Announces Unaudited Financial Results for the First Nine Months of Fiscal Year 2024](https://www.quantisnow.com/insight/ys-biopharma-announces-unaudited-financial-results-for-the-first-nine-5419885)
- 2024-04-18 12:15 UTC [SEC Form 6-K] [SEC Form 6-K filed by YS Biopharma Co. Ltd.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-ys-biopharma-co-ltd-5417581)
- 2024-04-18 12:11 UTC [Market Chatter] [YS Biopharma Granted Phase I Clinical Trial License Of Therapeutic Chronic Hepatitis B Virus Vaccine](https://www.quantisnow.com/insight/ys-biopharma-granted-phase-i-clinical-trial-license-of-therapeutic-5417564)
- 2024-04-18 12:00 UTC [YS Biopharma Granted Phase I Clinical Trial License of Therapeutic Chronic Hepatitis B Virus Vaccine](https://www.quantisnow.com/insight/ys-biopharma-granted-phase-i-clinical-trial-license-of-therapeutic-5417505)
- 2024-04-16 12:00 UTC [Earnings Date] [YS Biopharma to Report First Nine Months of Fiscal Year 2024 Financial Results on April 19, 2024](https://www.quantisnow.com/insight/ys-biopharma-to-report-first-nine-months-of-fiscal-year-5411991)
- 2024-04-09 19:30 UTC [Market Insight] [Chinese Biotech YS Biopharma's Next-Gen Rabies Vaccine Non-Inferior To Approved Competitor](https://www.quantisnow.com/insight/chinese-biotech-ys-biopharmas-next-gen-rabies-vaccine-non-inferior-to-approved-5400506)
- 2024-04-09 12:20 UTC [SEC Form 6-K] [SEC Form 6-K filed by YS Biopharma Co. Ltd.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-ys-biopharma-co-ltd-5399445)
- 2024-04-09 12:15 UTC [Market Chatter] [YS Biopharma shares are trading lower. The company announced interim results from the ongoing Phase 3 clinical trial of its PIKA Rabies Vaccine.](https://www.quantisnow.com/insight/ys-biopharma-shares-are-trading-lower-the-company-announced-interim-5399424)
- 2024-04-09 12:09 UTC [Market Insight] [12 Health Care Stocks Moving In Tuesday's Pre-Market Session](https://www.quantisnow.com/insight/12-health-care-stocks-moving-in-tuesdays-pre-market-session-5399406)
- 2024-04-09 12:09 UTC [Market Chatter] [YS Biopharma Highlights Interim Results Of Pivotal Phase 3 Clinical Study Of PIKA Rabies Vaccine; Says Results Indicate That The Pika Rabies Vaccine Has Successfully Met The Primary Endpoints Of The Trial](https://www.quantisnow.com/insight/ys-biopharma-highlights-interim-results-of-pivotal-phase-3-clinical-5399400)
- 2024-04-09 12:00 UTC [YS Biopharma Announces Positive Interim Results of Pivotal Phase 3 Clinical Study of PIKA Rabies Vaccine](https://www.quantisnow.com/insight/ys-biopharma-announces-positive-interim-results-of-pivotal-phase-3-5399328)
- 2024-04-03 12:10 UTC [SEC Form 6-K] [SEC Form 6-K filed by YS Biopharma Co. Ltd.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-ys-biopharma-co-ltd-5387304)
- 2024-04-03 12:00 UTC [YS Biopharma Announces Full Repayment of US$40,000,000 Loan Facility](https://www.quantisnow.com/insight/ys-biopharma-announces-full-repayment-of-us40000000-loan-facility-5387227)
- 2024-03-28 12:06 UTC [Market Insight] [12 Health Care Stocks Moving In Thursday's Pre-Market Session](https://www.quantisnow.com/insight/12-health-care-stocks-moving-in-thursdays-pre-market-session-5374142)
- 2024-03-05 21:31 UTC [Market Insight] [12 Health Care Stocks Moving In Tuesday's After-Market Session](https://www.quantisnow.com/insight/12-health-care-stocks-moving-in-tuesdays-after-market-session-5318146)
- 2024-03-05 13:06 UTC [SEC Form 6-K] [SEC Form 6-K filed by YS Biopharma Co. Ltd.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-ys-biopharma-co-ltd-5315865)
- 2024-03-05 13:00 UTC [YS Biopharma Announces Board Changes and Strategic Leadership Appointments in Chinese Subsidiaries](https://www.quantisnow.com/insight/ys-biopharma-announces-board-changes-and-strategic-leadership-appointments-in-5315785)
- 2024-02-23 13:15 UTC [SEC Form 6-K] [SEC Form 6-K filed by YS Biopharma Co. Ltd.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-ys-biopharma-co-ltd-5287046)
- 2024-02-22 22:06 UTC [SEC Form 6-K] [SEC Form 6-K filed by YS Biopharma Co. Ltd.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-ys-biopharma-co-ltd-5285727)
- 2024-02-22 22:00 UTC [Leadership Update] [YS Biopharma Announces Results of Extraordinary General Meeting held on February 22, 2024](https://www.quantisnow.com/insight/ys-biopharma-announces-results-of-extraordinary-general-meeting-held-on-5285609)
- 2024-02-20 11:17 UTC [SEC Form 6-K] [SEC Form 6-K filed by YS Biopharma Co. Ltd.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-ys-biopharma-co-ltd-5272857)
- 2024-02-17 01:25 UTC [SEC Form 6-K] [SEC Form 6-K filed by YS Biopharma Co. Ltd.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-ys-biopharma-co-ltd-5272740)
- 2024-02-17 01:20 UTC [YS Biopharma Announces Results of Extraordinary General Meeting and Responds to False Statements about the Meeting](https://www.quantisnow.com/insight/ys-biopharma-announces-results-of-extraordinary-general-meeting-and-responds-5272232)
- 2024-02-16 22:36 UTC [Leadership Update] [Shareholders Led by Yi Zhang Announce Successful Results of Removal of Directors and Election of New Directors of YS Biopharma Co., Ltd.](https://www.quantisnow.com/insight/shareholders-led-by-yi-zhang-announce-successful-results-of-removal-5271910)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/YS
- Earnings history: https://www.quantisnow.com/earnings/YS
- Dividend history: https://www.quantisnow.com/dividends/YS
- Insider transactions: https://www.quantisnow.com/insiders/YS
- Options chain: https://www.quantisnow.com/options/YS
- SEC 8-K filings only: https://www.quantisnow.com/company/YS/8-k
- RSS and alerts for YS: https://www.quantisnow.com/docs/rss-feeds.md